News & Events

2015 Year in Review and 2016 Outlook

by Insight Genetics
January 20, 2016

2015 was an exciting year for Insight Genetics with the formation of new partnerships, continued collaboration with existing partners, expansion of our leadership team, the launch of a CLIA-validated assay for non-small cell lung cancer (NSCLC), presentation of new research findings on triple negative breast cancer (TNBC), and new funding to continue the advancement of the company’s TNBC and NSCLC programs.   We look forward to an eventful 2016 as we continue to clinically validate and commercialize our breast and lung cancer assays, adapt these assays for compatibility with liquid biopsies and broader, multi-biomarker panels, expand collaborations with key academic institutions and commercial partners, and extend our services to the pharmaceutical industry. 

Insight ALK Screen Technology Clinically Validated

by Insight Genetics
December 30, 2015

The Archives of Pathology and Laboratory Medicine recently published an article by a group from the Department of Pathology and Genomic Medicine at Houston Methodist Hospital who performed a clinical validation of the Insight ALK Screen qPCR assay which is manufactured and distributed globally by QIAGEN as ALK RGQ RT-PCR Kit.

Page 1 of 15 (71 items)

|< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 >|